Contents
Issue 151 • February 2025
In association with
In Depth
The biggest challenges clinical trials will face in 2025
Investors optimistic about continued biotech and medtech IPO resurgence in 2025
ADCs breach barriers to become mainstream cancer treatment
WHO trial guidance goes beyond race and gender when tackling diversity
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
From Davids to Goliaths: the GLP-1RA gold rush
Radiopharmaceutical trials face extra complexities due to nuclear red tape